Politico sentään noteerasi Hallbergin et al/Virran tutkimuksen:https://www.politico.com/newsletters/mo ... eal-097047
— Virta Health study: A few months back, people were very excited about startup Virta Health, which attracted tons of money and some bold-font talents, like former CMS administrator Don Berwick (who’s on the company’s board). The firm hopes to reverse type 2 diabetes through a combination of changed diet (extremely low-carbohydrate) plus remote monitoring and coaching. The theory had some very small-scale validation, and it was put into practice in one — albeit unrandomized — study conducted in Indiana.
The study, published yesterday in Diabetes Today, enrolled 349 adults, of whom 262 were sorted into Virta’s intervention.
Those patients had seemingly spectacular results. Mike Payne, the company’s head of commercial and policy, was ebullient, saying it showed six in 10 patients achieved diabetes reversal (though 35 percent continue single-agent metformin).
The study served as proof-of-concept for Purdue University, which is now a client, Payne said.
Arien Malec, an executive with health IT company RelayHealth, was excited — with caveats — on Twitter. “A small molecule oral drug that reversed T2D, eliminated insulin therapy, normalized HbA1c, & caused 30lb weight loss would be the biggest blockbuster in history,” he tweeted. “That being said, an oral drug would still be in phase II trial right now.”
Jos jollakin lääkkeellä olisi saavutettu samanlaiset tulokset kuin ketokarppauksella, lööppien kirjasinkoolla ei olisi rajaa.